New trial aims to tailor breast cancer treatment using PET scans

NCT ID NCT06245889

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tests whether adjusting chemotherapy based on early PET scan results can improve outcomes for people with stage 2 or 3 triple negative breast cancer. Participants receive four cycles of chemotherapy plus the immunotherapy drug pembrolizumab. A PET scan after the first cycle helps guide whether additional chemotherapy is needed before surgery. The study aims to see if early changes in PET signals predict whether the cancer is completely gone at surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (immunotherapy) combined with chemotherapy drugs (paclitaxel, carboplatin, doxorubicin, cyclophosphamide, olaparib, capecitabine)
What this could lead to: If successful, this could help personalize treatment for triple negative breast cancer, potentially reducing unnecessary chemotherapy and improving outcomes.
What could go wrong: This is a small pilot study with only 30 participants, so results may not apply broadly. The approach is complex and may not improve response rates over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITING

Baltimore, Maryland, 21287, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITING

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.